Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for 4D Molecular [FDMT]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
BUY
71.43%
return 2.64%
SELL
50.00%
return 7.65%
Sist oppdatert26 apr 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

-1.19% $ 23.25

SELG 106000 min ago

@ $27.97

Utstedt: 14 feb 2024 @ 21:13

Avkastning: -16.88%

Forrige signal: feb 14 - 19:43

Forrige signal: Kjøp

Avkastning: 2.04 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):
Profile picture for 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology...

Stats
Dagens volum 317 415
Gjennomsnittsvolum 1.21M
Markedsverdi 1.19B
EPS $0 ( 2024-03-20 )
Neste inntjeningsdato ( $-0.730 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -9.01
ATR14 $0.0280 (0.12%)
Insider Trading
Date Person Action Amount type
2024-04-16 Bizily Scott Sell 1 250 Stock Option (Right To Buy)
2024-04-16 Bizily Scott Sell 500 Stock Option (Right To Buy)
2024-04-16 Bizily Scott Buy 1 250 Common Stock
2024-04-16 Bizily Scott Buy 500 Common Stock
2024-04-16 Bizily Scott Sell 1 750 Common Stock
INSIDER POWER
31.08
Last 99 transactions
Buy: 3 571 023 | Sell: 1 811 773

Volum Korrelasjon

Lang: -0.14 (neutral)
Kort: 0.80 (moderate)
Signal:(50.646) Neutral

4D Molecular Korrelasjon

10 Mest positive korrelasjoner
AFYA0.848
RMCF0.839
GOEV0.826
NTCT0.826
SLM0.821
IMGN0.818
TRMK0.817
NDAQ0.817
PRCT0.816
LSXMA0.816
10 Mest negative korrelasjoner
ISDX-0.838
ZIONP-0.827
TRHC-0.826
NVSAU-0.823
KSICU-0.822
IOAC-0.821
GRBK-0.815
XFIN-0.813
VRIG-0.812
BRIVU-0.81

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

4D Molecular Korrelasjon - Valuta/Råvare

The country flag 0.09
( neutral )
The country flag 0.05
( neutral )
The country flag 0.00
( neutral )
The country flag 0.48
( neutral )
The country flag -0.08
( neutral )
The country flag 0.07
( neutral )

4D Molecular Økonomi

Annual 2023
Omsetning: $20.72M
Bruttogevinst: $14.97M (72.26 %)
EPS: $-2.58
FY 2023
Omsetning: $20.72M
Bruttogevinst: $14.97M (72.26 %)
EPS: $-2.58
FY 2022
Omsetning: $3.13M
Bruttogevinst: $-751 000 (-24.00 %)
EPS: $-3.12
FY 2021
Omsetning: $18.04M
Bruttogevinst: $0.00 (0.00 %)
EPS: $-11.09

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.